International Journal of Internal Medicine

Objective To analyze the value of Suhuang cough capsule for cough variant asthma. Methods Cough variant asthma patients (n=72) from September 2020 to August 2022 were randomized, with 36 people each in the control group, the former with Suhuang cough capsules and the latter with conventional treatment. Compare the disappearance time of wheezing and other indicators. Results For cough relief time and asthma disappearance time, the test group data were (7.31 ± 2.56) d, (3.39 ± 0.92) d, and the control group data (11.57 ± 1.54) d, (6.68 ± 0.79) d were shorter (P <0.05). On the total response efficiency index: 97.22%, higher than 80.56% in the control group (P <0.05). For FVC and FEV1, at the end of treatment: trial group data were (3.91 ± 0.52) L, (3.05 ± 0.37) L, and control group data (2.71 ± 0.41) L, (3.01 ± 0.42) L were higher (P <0.05). Regarding the adverse reactions, the incidence rate was 5.56%, which was lower compared with the 22.22% data in the control group (P <0.05). For the sf-36 score, at the end of treatment: the trial group data (87.25 ± 3.69) and the control group data (80.34 ± 4.17) scores were higher (P <0.05). Conclusion Suhuang cough capsule for cough variant asthma has a lower incidence of adverse reactions, better prognosis, faster symptom relief, more obvious improvement of efficacy, and faster improvement of lung function.

cough variant asthma; adverse reactions; Suhuang cough capsule; curative effect